Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$1.05
-3.2%
$1.10
$0.80
$3.08
$42.93M-1.1218,483 shs485 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.03
-3.4%
$8.27
$2.20
$12.78
$239.53M-0.66190,051 shs30,941 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.40
+7.2%
$4.24
$2.32
$10.13
$400.31M2.29967,622 shs256,818 shs
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
$2.18
+1.9%
$2.03
$1.29
$3.51
$201.04M0.27185,788 shs7,366 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-4.42%+1.89%-6.09%-10.37%-48.08%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
+0.65%+0.21%+1.96%+122.62%+56.62%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+8.66%+10.40%+93.28%+104.75%-10.85%
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
-0.93%0.00%+2.44%-0.93%-26.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.3824 of 5 stars
3.53.00.00.03.31.70.0
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.1775 of 5 stars
3.55.00.00.02.02.50.6
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.5382 of 5 stars
1.21.00.00.02.72.50.0
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
2.9614 of 5 stars
3.85.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
3.00
Buy$5.50426.32% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.50
Moderate Buy$14.7563.36% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.50
Moderate Buy$5.83-21.12% Downside
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
3.50
Strong Buy$11.00404.36% Upside

Current Analyst Ratings Breakdown

Latest ANEB, DBVT, IPHA, and FULC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$9.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.00
5/15/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $3.00
5/15/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$10.00
5/5/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
4/24/2025
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.50 ➝ $11.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$15.73M15.72N/AN/A$7.27 per share1.24
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.99N/AN/A$3.80 per share1.95
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
$12.62M15.93N/AN/A$0.69 per share3.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-119.54%-108.08%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
-$8.19MN/A0.00N/AN/AN/AN/AN/A

Latest ANEB, DBVT, IPHA, and FULC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.04+$0.01-$0.04N/AN/A
5/1/2025Q1 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
17.51
17.51
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.22
2.22
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
18.44
18.44
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
0.92
2.92
N/A

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
0.16%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
31.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.09 million5.79 millionNot Optionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million20.18 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10053.98 million51.73 millionOptionable
Innate Pharma S.A. stock logo
IPHA
Innate Pharma
22092.18 million57.10 millionNot Optionable

Recent News About These Companies

Innate Pharma Announces €15M Investment by Sanofi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.04 -0.04 (-3.24%)
As of 11:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.03 -0.32 (-3.43%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$7.40 +0.50 (+7.17%)
As of 11:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$2.18 +0.04 (+1.92%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.